Table 1

Demographics and baseline disease characteristics

Certolizumab pegol–IR plus bimekizumab
(n=52)
Certolizumab pegol–IR plus placebo
(n=27)
Certolizumab pegol responders
(n=80)
Demographics, n (%)
Age, median (range), years53 (26–69)57 (30–67)58 (21–69)
Gender
 Male7 (13.5)4 (14.8)13 (16.3)
 Female45 (86.5)23 (85.2)67 (83.8)
Race
 Caucasian52 (100)27 (100)80 (100)
Duration of RA
 <2 years12 (23.1)8 (29.6)17 (21.3)
 ≥2 years40 (76.9)19 (70.4)63 (78.8)
History of extra-articular features7 (13.5)1 (3.7)7 (8.8)
Anti-CCP positive39 (75)19 (70.4)66 (82.5)
Rheumatoid factor positive39 (75)22 (81.5)64 (80.0)
Prior csDMARDs*49 (94.2)27 (100)79 (98.8)
 Methotrexate43 (82.7)22 (81.5)76 (95)
 Methotrexate sodium6 (11.5)4 (14.8)5 (6.3)
Concomitant csDMARDs†42 (80.8)26 (96.3)71 (88.8)
 Methotrexate29 (55.8)20 (74.1)63 (78.8)
 Methotrexate sodium6 (11.5)3 (11.1)3 (3.8)
Disease characteristics, mean (SD)
 SJC‡13.6 (6.4)16.2 (7.9)11.1 (5.4)
 TJC‡20.6 (10.5)26.2 (12.3)20.3 (9.8)
 PtAAP72.9 (15.5)73.1 (17.8)63.2 (21.4)
 PtGADA74 (14.2)77.7 (17)64.3 (20.9)
 HAQ-DI1.7 (0.6)1.9 (0.4)1.6 (0.6)
 DAS28(CRP)6.1 (0.7)6.2 (0.8)5.7 (0.8)
  • All patients received certolizumab pegol during the 8-week open-label run-in period.

  • *Prior medications include any medications that started prior to the start date of study medication.

  • †Concomitant medications are medications taken at least 1 day in common with the study medication, ie, whose start date is prior to the date of last study medication administration plus 14 days, and whose stop date is either missing, or on or after the date of first study medication administration.

  • ‡SJC and TJC were based on 66 and 68 counts, respectively.

  • Anti-CCP, anti-cyclic citrullinated peptide;csDMARD, conventional synthetic disease-modifying antirheumatic drug; DAS28(CRP), Disease Activity Score 28-joint count (C-reactive protein);HAQ-DI, Health Assessment Questionnaire–Disability Index;PtAAP, Patient’s Assessment of Arthritis Pain;PtGADA, Patient’s Global Assessment of Disease Activity;RA, rheumatoid arthritis;SCJ, swollen joint count;TJC, tender/painful joint count.